cbdMD (YCBD) Return on Capital Employed (2017 - 2026)
cbdMD (YCBD) posted Return on Capital Employed of 28.37% for Q4 2025, up 8.64% sequentially from 31.05% in Q3 2025, and up 9506.0% YoY from 0.3% in Q4 2024.
cbdMD (YCBD) Return on Capital Employed (2017 - 2026) Analysis & Trends
cbdMD has reported Return on Capital Employed for 9 years, with the latest figure at 28.37% in Q4 2025.
- Quarterly Return on Capital Employed rose 9506.0% year-over-year to 28.37% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 28.37% (up 9506.0% YoY) and the FY2025 annual result came in at 29.6%, up 3990.0% from the prior year.
- Return on Capital Employed grew to 28.37% in Q4 2025 per YCBD's latest filing, from 31.05% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 10.2% in Q1 2021 and troughed at 287.32% in Q2 2024.
- A 5-year average of 104.41% and a median of 92.54% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 21043 bps in 2024, then jumped 26107 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 40.82% in 2021, then tumbled by 328 bps to 174.78% in 2022, then fell by 15 bps to 201.66% in 2023, then jumped by 39 bps to 123.43% in 2024, then surged by 77 bps to 28.37% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 28.37%, 31.05%, and 26.25% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.54 Bn | 43.57 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.59 Bn | 39.94 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 32.41 Bn | 30.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.84 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.00 Bn | 19.34 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 19.03 Bn | 18.14 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.01 Bn | 11.48 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.15 Bn | 9.99 Bn | - | - |
| 10 | cbdMD | 5.39 Mn | 3.27 Mn | 3.04 Mn | -32.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.05% |
| Dec 31, 2025 | -28.37% |
| Sep 30, 2025 | -31.05% |
| Jun 30, 2025 | -26.25% |
| Mar 31, 2025 | -92.85% |
| Dec 31, 2024 | -123.43% |
| Sep 30, 2024 | -92.24% |
| Jun 30, 2024 | -287.32% |
| Mar 31, 2024 | -249.27% |
| Dec 31, 2023 | -201.66% |
| Sep 30, 2023 | -112.93% |
| Jun 30, 2023 | -76.89% |
| Mar 31, 2023 | -178.37% |
| Dec 31, 2022 | -174.78% |
| Sep 30, 2022 | -179.18% |
| Jun 30, 2022 | -101.38% |
| Mar 31, 2022 | -48.51% |
| Dec 31, 2021 | -40.82% |
| Sep 30, 2021 | -17.32% |
| Jun 30, 2021 | -15.36% |